The clinical use of array comparative genomic hybridization in the evaluation of patients with multiple congenital anomalies and/or mental retardation has recently led to the discovery of a number of novel microdeletion and microduplication syndromes. We present four male patients with overlapping molecularly defined de novo microdeletions of 16q24.3. The clinical features observed in these patients include facial dysmorphisms comprising prominent forehead, large ears, smooth philtrum, pointed chin and wide mouth, variable cognitive impairment, autism spectrum disorder, structural anomalies of the brain, seizures and neonatal thrombocytopenia. Although deletions vary in size, the common region of overlap is only 90 kb and comprises two known genes, Ankyrin Repeat Domain 11 (ANKRD11) (MIM 611192) and Zinc Finger 778 (ZNF778), and is located approximately 10 kb distally to Cadherin 15 (CDH15) (MIM 114019). This region is not found as a copy number variation in controls. We propose that these patients represent a novel and distinctive microdeletion syndrome, characterized by autism spectrum disorder, variable cognitive impairment, facial dysmorphisms and brain abnormalities. We suggest that haploinsufficiency of ANKRD11 and/or ZNF778 contribute to this phenotype and speculate that further investigation of non-deletion patients who have features suggestive of this 16q24.3 microdeletion syndrome might uncover other mutations in one or both of these genes.
INTRODUCTION
Whole-genome scanning technologies such as array comparative genomic hybridization (array CGH) and single-nucleotide polymorphism oligonucleotide arrays (SNP array) have enabled the detection of submicroscopic chromosomal aberrations, which previously escaped detection by routine cytogenetic and molecular cytogenetic techniques. [1] [2] [3] These methods have proven invaluable in the elucidation of genomic regions associated with mental retardation and/or congenital anomalies. [4] [5] [6] [7] [8] Several clinically distinct microdeletion and microduplication syndromes have been reported on the basis of data derived from these techniques, such as the 17q21.31 microdeletion syndrome 5 and the 1q41-1q42 microdeletion syndrome, 9 as well as microduplication syndromes involving 7q11.23 10, 11 and 17p11.2. 12 The phenotypic characteristics of microdeletion syndromes can be caused by haploinsufficiency of single genes, for example, TCF4 (MIM 602272) in Pitt-Hopkins syndrome, 13 EHMT1 (MIM 607001) in the 9q34.3 subtelomeric deletion syndrome 14 and either CREBBP (MIM 600140) or EP300 (MIM 602700) in Rubinstein-Taybi syndrome. 15, 16 The application of genome-wide array technologies with an increasing density of probes has led to the identification and localization of several genes associated with developmental disorders or abnormal brain development, 8 including CHD7 (MIM 608892) in CHARGE syndrome 17 and FOXG1(MIM 164874) in congenital Rett syndrome. 18 Aberrations of chromosome 16q with clinical relevance have rarely been reported. Before this report, interstitial deletions restricted to band 16q24.3 have not been described. There are only a few reports in medical literature with regard to patients with larger, cytogenetically visible deletions comprising this region, mostly because of an unbalanced complex chromosomal rearrangement. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] In this study, we aimed to characterize the clinical and molecular features of four patients with submicroscopic interstitial 16q24.3 microdeletions ascertained by genome-wide array analysis and to determine the shortest region of overlap (SRO) to identify candidate genes responsible for their overlapping phenotype.
PATIENTS AND METHODS

Patient 1
Patient 1 was ascertained at the age of 22 years when SNP array was performed because of mental retardation, autism spectrum disorder, dysmorphic features and congenital anomalies. He was born after an uncomplicated pregnancy, induced at 36-week gestation because of maternal preeclampsia. Growth parameters were appropriate for gestational age, with a birth weight between the 50th and 75th percentile. Head circumference was not measured at birth. He was diagnosed with congenital hip dysplasia, but had no other difficulties in the neonatal period. His psychomotor development was delayed. He walked independently at the age of 2.5 years and began using single words after the age of 4 years. At the age of 3 years, he was referred to a pediatric neurologist because of his developmental delay and epilepsy (absence and generalized epilepsy). Cerebral imaging with a computer tomography scan (CT-scan) showed colpocephaly, hypoplasia of the corpus callosum and heterotopia. Vision and audiological evaluations were normal. Routine chromosome analysis showed a normal male karyotype. At the age of 22 years, he was referred for reevaluation. He was moderately mentally retarded and showed behavior consistent with autism spectrum disorder. A Dutch formal test for autism spectrum disorders (AVZ-R 'Autisme-en Verwante stoornissenschaal-ZRevisie' , 1999) showed borderline results for the diagnosis of an autism spectrum disorder. His epilepsy was well under control and medical treatment was gradually stopped. On physical examination, he exhibited dysmorphic features, with a high forehead, bitemporal narrowing, long palpebral fissures, large ears, smooth philtrum, wide mouth and micrognathia (Figure 1c and d) . He had kyphoscoliosis and strabismus. His height was 175 cm (3-10th percentile), weight was 64 kg (50th percentile) and head circumference was 59.5 cm (90th percentile). Cardiac ultrasound revealed no abnormalities. Bone densitometry showed normal bone density. Genetic diagnostic evaluation with subtelomeric multiplex ligation-dependent probe amplification (MLPA, SALSA MLPA Kit P036, MRC Holland, Amsterdam, The Netherlands) was normal.
Patient 2
A cursory analysis of patient 2 has been included in a large Canadian autism cohort study, 30 and here we provide a more detailed clinical and molecular description. Patient 2 was ascertained at the age of 3 years and 3 months when SNP array analysis was performed because of developmental delay, autism spectrum disorder and dysmorphic features. He was born at term after an uncomplicated pregnancy and delivered by cesarean section on maternal indication. He was born with strikingly outstanding and asymmetric ears. On day 3, he developed low platelets. It was documented as having been caused by alloimmune idiopathic thrombocytopenic purpura (ITP) because of his mother's ITP. After treatment, his platelets remained within the normal range. Psychomotor development was delayed. At 21 months of age, he was unable to walk independently and used three single words with meaning. He was diagnosed with autism by formal tests at the age of 2 years by ADOS-1 (Autism Diagnostic Observation Schedule) and at the age of 3 years and 4 months by ADI-R (Autism Diagnostic Interview Revised). Psychometric testing at the age of 6 years and 5 months showed average results for nonverbal intelligence; The Naglieri Nonverbal Ability test score was at the 50th percentile and Test of nonverbal intelligence gave a nonverbal IQ of 100. Preschool Language Scale 4 (PLS-4) showed that auditory comprehension was severely delayed (1st percentile) and that expressive communication was moderately delayed (4th percentile). On physical examination, he had a height of 94 cm (10-25th percentile) and weight of 13.5 kg (10-25th percentile) and a head circumference of 49.5 cm (50th percentile). Facial dysmorphic features included frontal bossing, long palpebral fissures, a wide mouth with full lips, long and smooth philtrum, anteverted nares, pointed chin and large ears (ears originally outstanding/cupped and asymmetric, now after surgical correction) (Figure 1e ). Diagnostic studies, including routine G-banded chromosome analysis, FISH for the Williams syndrome microdeletion and molecular analysis for fragile X syndrome, were negative. CT-scan of the brain was normal and examination by an ophthalmologist did not show any abnormalities.
Patient 3
Patient 3 was ascertained at the age of 6 years and 3 months when array CGH analysis was performed because of mental retardation, dysmorphic features and congenital anomalies. He was born at term by vaginal delivery after an uncomplicated pregnancy and his size was appropriate for gestational age. At delivery, he was noted to have a skin rash and hepatosplenomegaly with thrombocytopenia. TORCH (toxoplasmosis, rubella, cytomegalovirus, herpes) infection was excluded and organomegaly and thrombocytopenia were resolved. He suffered a mild intracranial hemorrhage secondary to thrombocytopenia, and was diagnosed with a ventricular septal defect (VSD), patent foramen ovale (PFO), cleft mitral valve and left cryptorchidism in the newborn period. VSD and PFO were repaired at the age of 3 months. Routine G-banded chromosome analysis was normal. At the time of genetics consultation at the age of 6 years and 3 months, he was admitted to hospital for an acute parvovirus myocarditis and dilated cardiomyopathy with severely depressed biventricular function. Further evaluation revealed a history of developmental delay (he walked at the age of 3 years, and spoke his first words at 18-20 months), mental retardation and febrile seizures. On physical examination, he had a height on the 5-12th percentile and a head circumference on the 10th percentile. Dysmorphic features that were observed included a triangular face with a high forehead and frontal bossing, arched eyebrows, large ears, smooth philtrum, wide mouth, pointed chin and high palate (Figure 1f and g ). MRI of the brain revealed a posterior fossa arachnoid cyst, thinned corpus callosum, periventricular heterotopias, optic nerve hypoplasia and evidence for an old left hemorrhagic parietal infarct. The heterotopias were unilaterally localized along the lateral margin of the trigone of the right lateral ventricle extending along the temporal horn of the right lateral ventricle. Ophthalmic examination revealed high myopia, intermittent exotropia, horizontal nystagmus, and possible right amblyopia. Audiogram revealed moderate-to-severe bilateral mixed sensorineural and conductive hearing impairment. His complete blood count showed mild macrocytosis (MCV 92.4 FL; normal 76-90), with normal homocysteine and folate values. The cardiomyopathy and macrocytosis resolved, yet he developed complex partial seizures at the age of 7½ years, with EEG showing a seizure focus of the left temporal region. He continued to make progress in school. He meets criteria for autism under the ADOS.
Patient 4
Patient 4 was ascertained at the age of 8 years and 10 months when array CGH analysis was performed because of psychomotor retardation, features of autism spectrum disorder and dysmorphic features. He was born at term after an uneventful pregnancy by cesarean section because of breech presentation. His birth weight was 3850 g (50-90th percentile), but birth length and head circumference are unknown. In the first few weeks, there were feeding problems, probably caused by poor sucking. There was no hypotonia. Psychomotor development was slightly delayed with the child being able to sit independently at 12 months of age and able to walk independently at the age of 18 months. Language development was delayed. Throughout childhood, there were periods of obstipation. There were frequent ear infections. Hearing was tested normal. There is severe bilateral astigmatism. At the age of 7 years and 2 months, verbal IQ was 81 and performal IQ was 67, as assessed by the WISC III intelligence test. He was diagnosed with an Autism Spectrum Disorder (ASD)/Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) by a child psychologist and psychiatrist. There are no signs of epilepsy. On physical examination, he showed dysmorphic features with a high and broad forehead, mildly upslanting palpebral fissures, a double hair whorl, large ears, a preauricular tag and bilateral fusion of the central and lateral incisors (Figure 1h and i). His height was 126.3 cm (10-25th percentile), weight was 23.7 kg (5-25th percentile) and head circumference was 52.2 cm (50-75th percentile). Cardiac examination was normal. The left hand showed a single transverse palmar crease. Thumbs were slightly proximally placed. X-rays of the hands showed pseudo-epiphyses of the second metacarpals. Routine G-banded chromosome analysis showed a normal male karyotype. Molecular analysis for fragile X syndrome was negative. Complete blood count showed no abnormalities at the age of 8 years.
Methods
DNA was obtained from peripheral blood leukocytes and isolated according to standard procedures.
In patient 1 and 2 and both parental couples, a 500K SNP array analysis with the combined two-chip Affymetrix NspI and StyI GeneChip Human Mapping Commercial was performed according to the standard Affymetrix GeneChip protocol (Affymetrix Inc., Santa Clara, CA, USA). For CNV validation in patient 2, multiple SYBR Green-based qPCR assays were used (primer sequences available upon request) to measure relative copy number in the patient, parents and controls between this chromosome 16q24.3 and a control region (FOXP2). The same approach was used to validate a de novo 500 kb CNV gain at 3p14.2 near the common fragile site FRA3B in patient 2. Subsequently, patient 2 was also tested on the Affymetrix 6.0 array.
In patient 3 and his parents, a 244K oligo array analysis, according to the Agilent protocol (Agilent Technologies Inc., Santa Clara, CA, USA), was performed.
In patient 4 and his parents, a 105K oligo array according to the Agilent protocol was performed (design ID 019015, Agilent Technologies Inc.).
RESULTS
Clinical features
A summary of the clinical features of the four patients with a chromosome 16q24.3 microdeletion is shown in Table 1 . All patients show a prominent forehead and large ears. Moreover, patients 1-3 share other distinct features (Figure 1a-g ), including long smooth philtrum, broad mouth and pointed chin. These were not observed in patient 4 (Figure 1h and i) . In addition to variable cognitive impairment, ranging from moderate mental retardation to normal nonverbal IQ with moderate-to-severe speech delay, all four patients had either autistic features (patient 1) or met the diagnostic criteria for an ASD (patients 2-4). Interestingly, brain abnormalities, including structural anomalies and neuronal migration disorders, were noticed in two of the three patients who underwent brain imaging (patient 1 and 3). Epilepsy and (transient) thrombocytopenia were each noticed in two of the four patients. Nonspecific ocular problems were seen in three of the four patients. One patient, patient 3, with the largest deleted region, had a ventricular septal defect and cleft mitral valve.
Molecular findings
The de novo CNV results observed in the four patients are summarized in Table 1 In all four cases, analysis of both parents showed normal copy numbers for the deleted regions, suggesting a de novo origin of the deletions. These four chromosome 16q24.3 deletion cases are the only cases that have been detected in a total cohort of more than 3000 patients with developmental delay and/or autism or congenital anomalies. The same region was interrogated over 1000 population controls 31 and found not to be copy number variable. The Database of Genomics Variants 32 shows one CNV (Variation_4018) at this site, 33 involving the first two exons of ANKRD11 but not ZNF778, but it is not found in other studies.
DISCUSSION
We present detailed clinical and molecular features of four patients with microdeletions within the chromosomal band 16q24.3. The four patients have autistic features or a diagnosis of ASD, variable cognitive impairment and facial dysmorphism, and share a 90 kb overlapping region comprising two annotated genes, Ankyrin Repeat Domain 11 (ANKRD11) and zinc finger 778 (ZNF778) (Figure 2 ). The level of cognitive impairment that was observed in these four patients is considerably variable, ranging from moderate mental retardation in patient 1 and 3 to a normal nonverbal IQ with moderate-to-severe speech delay in patient 2. Patient 2 showed a remarkable discrepancy between his verbal and nonverbal capacities in disadvantage of speech/ auditory development. A reverse discrepancy in IQ levels, however less extreme, was reported in patient 4 who had a borderline-to-normal verbal IQ of 81 and a mildly impaired nonverbal IQ of 67. Remarkably, both patients 1 and 3 have structural brain abnormalities, including hypoplasia of corpus callosum, colpocephaly/dilated ventricles, as well as periventricular heterotopias that might be causative for the epilepsy these two patients experienced. They share a deletion interval comprising ANKRD11, ZNF778 and CDH15, suggesting that haploinsufficiency for one or more of these genes is involved in neuronal migration and causes the gray matter heterotopias in patient 1 and 3. The localization of the heterotopias in patient 1 was likely bilateral, but no further details were available by cerebral imaging for this patient. The heterotopias in patient 3, however, were unilaterally localized, which raises the possibility that this migrational defect was caused by an (in utero) acquired event rather than by a genetic defect. Both patients 2 and 3 had temporary thrombocytopenia, although the neonatal thrombocytopenia in patient 2 was attributed to his mother's ITP. Nonspecific ocular problems were noted in three of the four patients. Features that were only observed in patient 3 (with the largest deleted region) were a congenital heart defect, unilateral cryptorchidism and sensorineural hearing impairment. Patient 2 also carried a 500 kb de novo gain at 3p14.2 at the FRA3B (MIM 601153) locus, which may also contribute to his phenotype; however, patient 2 had no other specific features.
By molecular characterization of these four overlapping deletions in 16q24.3, two likely candidate genes for the observed autism phenotype with cognitive impairment were present in the SRO. A third gene, Cadherin 15 (CDH15), is located just proximal to the SRO and is involved in the deletion observed in patients 1, 3 and 4 ( Figure 2 ). CDH15 does not seem to be involved in the deletion in patient 2. The possibility that a position effect or disruption of gene regulatory elements could also create a functional null allele for CDH15 in this patient is not excluded. The potential involvement of CDH15 is of particular interest, a nonsynonymous variants of this gene have been identified in a cohort of mentally disabled patients. 34 However, the group of nonaffected controls in this study was relatively small and the segregation of variants in unaffected family members has not been tested consistently nor was it in agreement with the presumed pathogenicity of the detected variant. Of interest, a recently published genome-wide association study among cases with ASD identified common genetic variants on 5p14.1 that are associated with susceptibility to ASD. The nearby genes, CDH9 (MIM 609974) and CDH10 (MIM 604555), are also members of the Cadherin gene family involved in neuronal cell adhesion. This implicates a role of CDH9 and CDH10 and possibly of other members of the Cadherin family in the pathogenesis of ASD by affecting neuronal cell adhesion. 35 Haploinsufficiency for either or both ANKRD11 and ZNF778 is an attractive explanation for the syndromic autism phenotype, with variable cognitive impairment observed in the four patients. ANKRD11 encodes a member of the family of ankyrin repeat containing cofactors that interacts with p160 nuclear receptor coactivators and histone deacetylases corepressors and inhibits ligand-dependent transcriptional activation of target genes by nuclear receptors. 36 Therefore, haploinsufficiency of ANKRD11 may disrupt transcription regulation. Disruption of epigenetic processes has been shown to have a role in causing mental retardation. deletion syndrome and mutations in either CREBBP or EP300 in the Rubinstein-Taybi syndrome. In these cases, mental retardation might be caused by epigenetic effects on the expression of genes that are not themselves mutated. 37 Interestingly, Barberic et al 38 described a mouse mutant, named Yoda, with a missense mutation in the Ankrd11 gene. Homozygous knockout Yoda mice are not viable and die during embryogenesis. This suggests that the gene has a crucial function in embryonic development. A major feature of heterozygous mutant mice is reduced bone mineral density. They also show cranio-facial abnormalities, such as shortened snouts, wider skulls, deformed nasal bones and failure of the interfrontal suture to close. Body size is reduced and with aging many Yoda mice developed kyphosis. 38 Mild kyphoscoliosis was seen only in the oldest patient (patient 1); however, an examination of bone density in this patient showed normal results. On the basis of in silico data, ANKRD11 is widely expressed, including in several brain regions (amygdala, parietal lobe, occipital lobe and cerebellum) and the heart (UCSC Genome Browser, Microarray Expression Data, Unigene).
The other gene localized in the SRO, ZNF778, encodes a member of the extensive family of KRAB-domain zinc finger proteins. On the basis of available in silico data, this gene is also expressed in several tissues, including the brain and heart (Unigene). KRAB-domain zinc finger proteins are found in transcription regulatory complexes, which are directed to the regulatory elements of target genes through the C2H2 zinc finger domains that recognize specific DNA binding sites. Moreover, several human zinc finger genes have been associated with MR: ZNF41 (MIM 314995), ZNF81 (MIM 314998) and ZNF674 (MIM 300573) with X-linked MR [39] [40] [41] and ZNF385B (MIM 612344) with the 2q31.2 deletion syndrome. 41 Therefore, haploinsufficiency of ZNF778 might also, or exclusively, be involved in the phenotype observed in the reported patients. Table 2 provides an overview of these and other interesting genes that are involved in nonoverlapping deleted regions. Proposed functions, phenotype in knockout mice (if available), previously reported cases and the possible clinical correlation of haploinsufficiency of these genes with the observed phenotype in our patients are indicated. Interestingly, the deletion interval of patients 2 and 3 with transient thrombocytopenia comprises the gene ZFPM1 (FOG1) (MIM 601950), which is involved in the regulation of the expression of genes during erythroid and megakaryocytic differentiation. On the basis of available data, we were unable to recognize a candidate gene for the congenital heart defect observed in patient 3.
In conclusion, we hypothesize that ANKRD11 and ZNF778 are strong candidate genes for the observed core phenotype of this novel 16q24.3 microdeletion syndrome comprising autism spectrum disorder, variable cognitive impairment, facial dysmorphism and brain abnormalities, although a role of one or more of the other genes in the deleted regions of individual patients is not excluded. Moreover, the involvement of ANKRD11 and ZNF778 warrants further studies searching for ANKRD11 and/or ZNF778 mutations in patients with a similar phenotype, but without 16q24 abnormalities by molecular karyotyping. Follow-up of known patients might give answers to the possible occurrence of other phenotypic features. Moreover, the identification of new cases with overlapping deletions is needed to extend phenotypic knowledge and to confirm or even further narrow down the critical region of involved genes.
